Merida Biosciences is developing antibody-like drugs designed to selectively eliminate disease-driving autoantibodies while sparing healthy components of the immune system. Graves' disease, which stems from the immune system's attack on the thyroid gland, is the startup’s lead disease target.
Check out news from Opala, Equiva, Sling Therapeutics, Quil, and Third Rock Ventures.
This report highlights what Paubox says is a broken infrastructure at the heart of this issue, exposing millions to preventable risks.
Septerna has science from a Nobel laureate and technology that finds new ways to drug GPCRs, well-validated receptors targeted by about one-third of FDA-approved medicines. According to CEO Jeff Finer, the startup is kicking off a second golden age of GPCR drug development.
Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup's first disease target.
The company has a 10,000-patient prospective trial with Geisinger fully enrolled to test CancerSEEK, a test developed at Johns Hopkins University.
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
Get your IV treatment from wherever you are. These top companies provide mobile IV therapy administered by experienced nurses in NYC and beyond.
Deals worth $50 million or more are becoming more frequent, even in Series A. But a VC investor said underlying drivers in life sciences are different from the technology sector.
The company secured $60 million in a Series A round from Third Rock and Takeda, plus a partnership with Takeda.
Third Rock Ventures has incubated, funded and launched another startup, Goldfinch Bio, committing $55M to its mission to modernize the treatment of kidney disease.
Boston-based Third Rock Ventures announced Monday that it had closed its largest fund to date, raising $616 million for new investments in neurology, immunology, genetic disorders and more.
Discover nine top caregiver services with flexible scheduling to fit changing routines, shift work or evolving health needs — featuring trusted platforms and in-home care providers.
Relay Therapeutics is aiming to identify the way proteins in cells move and shift and morph, and this understanding can help open the door to new, more effective drugs.
Massachusetts-based NinePoint Medical has raised about $30.7 million to go toward its medical imaging technology that allows visibility to large areas of tissue in order to more precisely detect areas that would need to be biopsied.
Decibel Therapeutics, a Third Rock-backed startup, was just launched in Boston to treat a wide range of hearing loss disorders. It just closed out a $52 million Series A.
With precision medicine in its infancy, it’s still difficult to determine which chemotherapy drugs are appropriate for a patient. MIT researchers have developed a device the size of a grain of rice that can be implanted into a patient, and carry small doses of up to 30 different drugs that can be delivered in tandem. When implanted in […]
Nature’s been a fantastically bountiful source of medicine, sure. But turns out the drug compounds found secreted by a sea sponge or on the underside of a log have very elaborate chemical structures. When used for unintended purposes like, say, treating humans, these compounds can both help and harm. Third Rock Ventures just funneled an impressive $45 million to launch […]